In situ loading of skin dendritic cells with apoptotic bleb-derived antigens for the induction of tumor-directed immunity

The generation and loading of dendritic cells (DC) ex-vivo for tumor vaccination purposes is laborious and costly. Direct intradermal (i.d.) administration of tumor-associated antigens could be an attractive alternative approach, provided that efficient uptake and cross-presentation by appropriately activated skin DCs can be achieved. Here, we compare the efficiency of i.d. delivery of relatively small apoptotic blebs (diameter ∼0.1–1 μm) derived from MART-1 transduced acute myeloid leukemia (AML) HL60 cells, to that of larger apoptotic cell remnants (ACR; 2–10 μm) in a physiologically highly relevant human skin explant model. Injection of either fluorescently-labelled ACRs or blebs alone did not affect the number or distribution of migrated DC subsets from skin biopsies after 48 hours, but resulted in a general up-regulation of the co-stimulatory molecules CD83 and CD86 on skin DCs that had ingested apoptotic material. We have previously shown that i.d. administration of GM-CSF and IL-4 resulted in preferential migration of a mature and highly T cell-stimulatory CD11hiCD1a+CD14− dermal DC subset. Here, we found that co-injection of GM-CSF and IL-4 together with either ACRs or blebs resulted in uptake efficiencies within this dermal DC subset of 7.6% (±6.1%) and 19.1% (±15.9%), respectively, thus revealing a significantly higher uptake frequency of blebs (P < 0.02). Intradermal delivery of tumor-derived blebs did not affect the T-cell priming and TH-skewing abilities of migratory skin DC. Nevertheless, in contrast to i.d. administration of ACR, the injection of blebs lead to effective cross-presentation of MART-1 to specific CD8+ effector T cells. We conclude that apoptotic bleb-based vaccines delivered through the skin may offer an attractive, and broadly applicable, cancer immunotherapy.

[1]  G. Ossenkoppele,et al.  Apoptotic blebs from leukemic cells as a preferred source of tumor-associated antigen for dendritic cell-based vaccines , 2014, Cancer Immunology, Immunotherapy.

[2]  T. D. de Gruijl,et al.  Dendritic Cell Plasticity in Tumor-Conditioned Skin: CD14+ Cells at the Cross-Roads of Immune Activation and Suppression , 2013, Front. Immunol..

[3]  M. Stratton,et al.  Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. D. de Gruijl,et al.  IL-10 Conditioning of Human Skin Affects the Distribution of Migratory Dendritic Cell Subsets and Functional T Cell Differentiation , 2013, PloS one.

[5]  M. Olson,et al.  Blebs produced by actin–myosin contraction during apoptosis release damage-associated molecular pattern proteins before secondary necrosis occurs , 2013, Cell Death and Differentiation.

[6]  John P. Moore,et al.  Clinical Adjuvant Combinations Stimulate Potent B-Cell Responses In Vitro by Activating Dermal Dendritic Cells , 2013, PloS one.

[7]  S. H. van der Burg,et al.  Intradermal Delivery of TLR Agonists in a Human Explant Skin Model: Preferential Activation of Migratory Dendritic Cells by Polyribosinic-Polyribocytidylic Acid and Peptidoglycans , 2013, The Journal of Immunology.

[8]  E. Klechevsky,et al.  Immunoglobulin-like transcript receptors on human dermal CD14+ dendritic cells act as a CD8-antagonist to control cytotoxic T cell priming , 2012, Proceedings of the National Academy of Sciences.

[9]  J. Landsberg,et al.  Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation , 2012, Nature.

[10]  D. Pankov,et al.  Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias. , 2012, Blood.

[11]  E. Klechevsky,et al.  The differential production of cytokines by human Langerhans cells and dermal CD14(+) DCs controls CTL priming. , 2012, Blood.

[12]  F. Nestle,et al.  Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation , 2012, The Journal of experimental medicine.

[13]  V. Soumelis,et al.  Characterization of resident and migratory dendritic cells in human lymph nodes , 2012, The Journal of experimental medicine.

[14]  S. Calderwood,et al.  The Role of Heat Shock Proteins in Antigen Cross Presentation , 2012, Front. Immun..

[15]  T. D. de Gruijl,et al.  The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma. , 2012, Current topics in microbiology and immunology.

[16]  B. Fox,et al.  Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy , 2011, Clinical Cancer Research.

[17]  J. Yewdell,et al.  DRiPs solidify: progress in understanding endogenous MHC class I antigen processing. , 2011, Trends in immunology.

[18]  S. Meijer,et al.  Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation. , 2011, Blood.

[19]  D. Kaplan.  In vivo function of Langerhans cells and dermal dendritic cells. , 2010, Trends in immunology.

[20]  T. D. de Gruijl,et al.  Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation , 2010, Cancer Immunology, Immunotherapy.

[21]  G. Adema,et al.  Mouse dendritic cells matured by ingestion of apoptotic blebs induce T cells to produce interleukin-17. , 2009, Arthritis and rheumatism.

[22]  S. H. van der Burg,et al.  Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells. , 2009, Molecular immunology.

[23]  G. Chinnadurai,et al.  BH3-only proteins in apoptosis and beyond: an overview , 2008, Oncogene.

[24]  H. Ueno,et al.  Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. , 2008, Immunity.

[25]  Yufang Shi,et al.  Apoptotic Cells Induce Immunosuppression through Dendritic Cells: Critical Roles of IFN-γ and Nitric Oxide1 , 2008, The Journal of Immunology.

[26]  S. Gibbs,et al.  Transcriptional profiling of human skin‐resident Langerhans cells and CD1a+ dermal dendritic cells: differential activation states suggest distinct functions , 2008, Journal of leukocyte biology.

[27]  T. D. de Gruijl,et al.  Inducing Antitumor T Cell Immunity: Comparative Functional Analysis of Interstitial Versus Langerhans Dendritic Cells in a Human Cell Line Model , 2008, The Journal of Immunology.

[28]  H. Jäck,et al.  After shrinkage apoptotic cells expose internal membrane-derived epitopes on their plasma membranes , 2008, Cell Death and Differentiation.

[29]  S. Meijer,et al.  Intradermal CpG-B Activates Both Plasmacytoid and Myeloid Dendritic Cells in the Sentinel Lymph Node of Melanoma Patients , 2007, Clinical Cancer Research.

[30]  T. D. de Gruijl,et al.  A Postmigrational Switch among Skin-Derived Dendritic Cells to a Macrophage-Like Phenotype Is Predetermined by the Intracutaneous Cytokine Balance1 , 2006, The Journal of Immunology.

[31]  K. Schäkel,et al.  Fast Appearance of Donor Dendritic Cells in Human Skin: Dynamics of Skin and Blood Dendritic Cells after Allogeneic Hematopoietic Cell Transplantation , 2006, Transplantation.

[32]  A. Morelli.  The Immune Regulatory Effect of Apoptotic Cells and Exosomes on Dendritic Cells: Its Impact on Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[33]  S. Meijer,et al.  Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells. , 2005, The American journal of pathology.

[34]  V. Allan,et al.  Active relocation of chromatin and endoplasmic reticulum into blebs in late apoptotic cells , 2005, Journal of Cell Science.

[35]  P. V. van Diest,et al.  Local Administration of Granulocyte/Macrophage Colony-stimulating Factor Increases the Number and Activation State of Dendritic Cells in the Sentinel Lymph Node of Early-Stage Melanoma , 2004, Cancer Research.

[36]  S. Aiba,et al.  Targeting Apoptotic Tumor Cells to FcγR Provides Efficient and Versatile Vaccination Against Tumors by Dendritic Cells 1 , 2003, The Journal of Immunology.

[37]  D. Curiel,et al.  Prolonged Maturation and Enhanced Transduction of Dendritic Cells Migrated from Human Skin Explants After In Situ Delivery of CD40-Targeted Adenoviral Vectors1 , 2002, The Journal of Immunology.

[38]  R. Steinman,et al.  Immune Tolerance After Delivery of Dying Cells to Dendritic Cells In Situ , 2002, The Journal of experimental medicine.

[39]  R. Doms,et al.  Diversity of receptors binding HIV on dendritic cell subsets , 2002, Nature Immunology.

[40]  S. Stevanović.  Identification of tumour-associated t-cell epitopes for vaccine development , 2002, Nature Reviews Cancer.

[41]  Simon C Watkins,et al.  Dermal-resident CD14+ cells differentiate into Langerhans cells , 2001, Nature Immunology.

[42]  Erik Hooijberg,et al.  Immortalization of Human CD8+ T Cell Clones by Ectopic Expression of Telomerase Reverse Transcriptase1 , 2000, The Journal of Immunology.

[43]  C. Bayerl,et al.  Langerhans cells enclosing sunburn cells in acute UV erythema in vivo , 1999, Archives of Dermatological Research.

[44]  F. Geissmann,et al.  Transforming Growth Factor (cid:98) 1, in the Presence of Granulocyte/Macrophage Colony-stimulating Factor and Interleukin 4, Induces Differentiation of Human Peripheral Blood Monocytes into Dendritic Langerhans Cells , 2022 .

[45]  C. Thompson,et al.  Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. , 1993, Journal of immunology.

[46]  C. Perreault,et al.  Study of Langerhans cells after allogeneic bone marrow transplantation. , 1984, Blood.